关于我们
ABOUT US
公司简介
宜昌博仁凯润药业有限公司成立于2019年8月，主要批量生产国际热销的的PEG linkER类链接剂产品,同时还开发和生产PEG linkER修饰过的纳米脂质体配方材料、亲脂类纳米颗粒配方材料，为国内外急需的药物定向输送行业提供可靠材料和技术支持。现有的药物定向传输技术多以开发新的生物靶向分子来导引现有的药物，宜昌博仁凯润药业有限公司开发的药物传输中间体是利用现有的纳米颗粒导向技术，实现已有靶向分子和现有的治疗制剂的快速结合（利用我们的聚乙二醇链接剂技术），从而可以快速开发出成千上万种靶向分子制导的治疗制剂的药物库，然后与临床治疗结合，可以筛选出最适合治疗病人的医疗制剂，从而实现对病人的最佳个性化治疗。
Founded in August 2019, Yichang Boren Kelun Pharmaceutical Co., Ltd. is mainly engaged in mass production of PEG linkER linkER linker products, and also develops and produces PEG linkER modified nano-liposome formula materials and lipophilic nanoparticle formula materials. To provide reliable materials and technical support for the urgently needed drug delivery industry at home and abroad. The existing targeted drug delivery technology is mainly to develop new biological targeted molecules to guide existing drugs. The drug delivery intermediate developed by Yichang Boren Kelun Pharmaceutical Co., Ltd. utilizes the existing nanoparticle guidance technology to realize the rapid combination of existing targeted molecules and existing therapeutic agents (using our polyethylene glycol linker technology). Thus, a drug library of thousands of targeted molecular guided therapeutic agents can be rapidly developed, and then combined with clinical treatment, the most suitable medical agents can be selected to treat patients, so as to achieve the best personalized treatment for patients.
